Prosecution Insights
Last updated: November 20, 2026

Novo Nordisk Inc.

Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering

28 pending office actions • 12 art units • 24 examiners • 0 of 28 (0%) have an AI response strategy ready • 32 patents granted in the last 365 days

Analysis

Novo Nordisk Inc. has 27 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 23 distinct examiners and 11 distinct art units, showing that the pending portfolio is spread across examiners while remaining within a more limited set of technical examination groups.

CHANDRA, GYAN is the busiest examiner, with 2 pending matters. That assignment represents only a small portion of the company’s pending activity, so prosecution planning should account for varied examiner practices rather than rely on one recurring examiner relationship. Art-unit tracking may provide a useful organizing layer for coordinating responses across the portfolio.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

28
Total Pending OAs
15
Non-Final OAs
12
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
2
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (2)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

12
Hard (43%)
12
Medium (43%)
4
Easy (14%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only7 (25%)
§102 only1 (4%)
§112 only2 (7%)
Double-patenting only2 (7%)
Double-patenting + other4 (14%)
Multi-statute (no §101)12 (43%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

21
Life Sciences
75% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
7
Mechanical / Eng
25% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

280 h
Manual time on pending OAs
56 h
Time saved (low, 20%)
98 h
Time saved (mid, 35%)
2.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CHANDRA, GYAN 2 71.3% +27.6%
HELLMAN, KRISTINA M 2 65.1% +55.6%
ARCORIA, PAUL JOSEPH 2 66.7% +50.0%
BRADLEY, CHRISTINA 2 62.4% +32.7%
COFFA, SERGIO 1 61.2% +32.3%
KONOPELSKI SNAVEL, SARA ELIZABETH 1 36.2% +35.5%
BENAVIDES, JENNIFER ANN 1 50.8% +48.2%
GALSTER, SAMUEL LEONARD 1 51.2% +40.2%
KASHYAP, ESHA PRAKASH 1 100.0% +0.0%
ANTHOPOLOS, PETER 1 57.6% +58.6%

Hard Cases (12)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18015444 METHODS FOR TREATING CARDIOVASCULAR DISEASE HOWARD, ZACHARY C 26d
19415046 PEPTIDE ANALOGS AND METHODS OF USING THE SAME CHANDRA, GYAN —
19355693 ANTAGONISTS OF HUMAN FGF23 BENAVIDES, JENNIFER ANN —
18837928 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF ARCORIA, PAUL JOSEPH —
18681845 INGESTIBLE DEVICE KASHYAP, ESHA PRAKASH —
18578485 SODIUM N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLATE POLYMORPHIC FORM A ANTHOPOLOS, PETER —
18252056 COMPOUNDS AND THEIR USE IN TREATMENT OF TACHYKININ RECEPTOR MEDIATED DISORDERS BRADLEY, CHRISTINA —
17782313 FIXED DOSE INJECTION DEVICE FARRAR, LAUREN PENG —

Interview Candidates (13)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
19463848 SEMAGLUTIDE IN MEDICAL THERAPY COFFA, SERGIO —
19415046 PEPTIDE ANALOGS AND METHODS OF USING THE SAME CHANDRA, GYAN —
19404431 TRI-AGONISTS OF THE GLP-1, GIP, AND AMYLIN RECEPTORS AND USES THEREOF HELLMAN, KRISTINA M —
19378410 SEMAGLUTIDE IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE KONOPELSKI SNAVEL, SARA ELIZABETH —
19355693 ANTAGONISTS OF HUMAN FGF23 BENAVIDES, JENNIFER ANN —
18839945 METHODS FOR TREATING SUBJECTS WITH ABDOMINAL OBESITY HYPERTRIGLYCERIDEMIA AND/OR IMPAIRED GLUCOSE ARCORIA, PAUL JOSEPH —
18837928 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF ARCORIA, PAUL JOSEPH —
18723131 PROCESS FOR THE BACKBONE DEPROTECTION OF OLIGONUCLEOTIDES CONTAINING A TERMINAL ALKYL PHOSPHONATE GROUP GALSTER, SAMUEL LEONARD —

Top Art Units

Art UnitApps
3783 7
1654 4
1658 3
1674 3
1621 2
1693 2
1626 2
1675 1
1641 1
1635 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19463848 SEMAGLUTIDE IN MEDICAL THERAPY COFFA, SERGIO 1658 DP Final Rejection — Pending Jan 29, 2026
19415046 PEPTIDE ANALOGS AND METHODS OF USING THE SAME CHANDRA, GYAN 1674 §103§112 Non-Final OA — Pending Dec 10, 2025
19404431 TRI-AGONISTS OF THE GLP-1, GIP, AND AMYLIN RECEPTORS AND USES THEREOF HELLMAN, KRISTINA M 1654 §112 Non-Final OA — Pending Dec 01, 2025
19378410 SEMAGLUTIDE IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE KONOPELSKI SNAVEL, SARA ELIZABETH 1658 §103§112DP Non-Final OA — Pending Nov 04, 2025
19355693 ANTAGONISTS OF HUMAN FGF23 BENAVIDES, JENNIFER ANN 1675 §102§112 Non-Final OA — Pending Oct 10, 2025
18839945 METHODS FOR TREATING SUBJECTS WITH ABDOMINAL OBESITY HYPERTRIGLYCERIDEMIA AND/OR IMPAIRED GLUCOSE ARCORIA, PAUL JOSEPH 1621 §103 Non-Final OA — Pending Aug 20, 2024
18837928 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF ARCORIA, PAUL JOSEPH 1621 §103§112 Non-Final OA — Pending Aug 13, 2024
18723131 PROCESS FOR THE BACKBONE DEPROTECTION OF OLIGONUCLEOTIDES CONTAINING A TERMINAL ALKYL PHOSPHONATE GROUP GALSTER, SAMUEL LEONARD 1693 §103 Non-Final OA — Pending Jun 21, 2024
18673424 Combination Therapy for Treatment of Liver Disease BRADLEY, CHRISTINA 1654 §103 Non-Final OA — Pending May 24, 2024
18681845 INGESTIBLE DEVICE KASHYAP, ESHA PRAKASH 3783 §102§103 Final Rejection — Pending Feb 06, 2024
18426412 GLP-1 RECEPTOR AGONISTS IN DEMENTIA CHANDRA, GYAN 1674 §102§103DP Non-Final OA — Pending Jan 30, 2024
18578485 SODIUM N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLATE POLYMORPHIC FORM A ANTHOPOLOS, PETER 1626 §102§103§112 Non-Final OA — Pending Jan 11, 2024
18242868 FACTOR X BINDERS ENHANCING FX ACTIVATION SZPERKA, MICHAEL EDWARD 1641 §112DP Final Rejection 5d overdue Pending Sep 06, 2023
18280092 RNAI CONJUGATES AND USES THEREOF KONOPKA, CATHERINE ANNE 1635 §103DP Final Rejection — Pending Sep 01, 2023
18271985 A TORSION SPRING DRIVEN FIXED DOSE INJECTION DEVICE MEDWAY, SCOTT J 3783 §102 Final Rejection — Pending Jul 12, 2023
18252056 COMPOUNDS AND THEIR USE IN TREATMENT OF TACHYKININ RECEPTOR MEDIATED DISORDERS BRADLEY, CHRISTINA 1654 §103§112 Non-Final OA — Pending May 08, 2023
18020386 INGESTIBLE DRUG DELIVERY DEVICE GONZALEZ, LEI NMN 3783 §103 Non-Final OA 26d Pending Feb 08, 2023
18019404 SYSTEMIC DELIVERY OF OLIGONUCLEOTIDES CHO, DAVID H 1693 §103Other Final Rejection 53d Pending Feb 02, 2023
18015444 METHODS FOR TREATING CARDIOVASCULAR DISEASE HOWARD, ZACHARY C 1674 §103§112 Non-Final OA 26d Pending Jan 10, 2023
17913292 Solid Dispersions of Amorphous 3,4-Diphenyl-4,5-Dihydro-1H-Pyrazole Derivatives, Compositions Comprising them and Uses Thereof as Cannabinoid CB1 Receptor Inhibitors SAEED, KAMAL A 1626 §112 Final Rejection — Pending Sep 21, 2022
17800747 GLP-1 COMPOSITIONS AND USES THEREOF ATKINSON, JOSHUA ALEXANDER 1612 DP Final Rejection 31d overdue Pending Aug 18, 2022
17782313 FIXED DOSE INJECTION DEVICE FARRAR, LAUREN PENG 3783 §102§103 Non-Final OA — Pending Jun 03, 2022
17782003 AN INJECTION DEVICE FOR DELIVERING A LIQUID DRUG NORTH, ISABELLA SARAH HYO SO 3783 §102§103 Non-Final OA — Pending Jun 02, 2022
17638483 PROCESS FOR PRODUCING A TABLET COMPRISING GLP-1 PEPTIDES HELLMAN, KRISTINA M 1654 §102§112Other Final Rejection — Pending Feb 25, 2022
17616283 APPLICATION OF ANTIARRHYTHMIC AGENTS TO STEM CELL DERIVED CARDIOMYOCYTES AND USES THEREOF TRAN, KHOA NHAT 1632 §103 Final Rejection — Pending Dec 03, 2021
17614077 DUAL CHAMBER DRUG RESERVOIR AND STOPPER THEREFOR RITCHIE, HADEN MATTHEW 3783 §102§103 Final Rejection — Pending Nov 24, 2021
17403357 COMPOSITIONS COMPRISING A DELIVERY AGENT AND PREPARATION THEREOF REYNOLDS, FRED H 1658 §103§112Other Non-Final OA — Pending Aug 16, 2021
17286639 ZERO-POINT ADJUSTMENT OF PREFILLED DRUG DELIVERY DEVICE ZAMORY, JUSTIN L 3783 §103 Final Rejection — Pending Apr 19, 2021

Managing Novo Nordisk Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Novo Nordisk Inc. have?

Novo Nordisk Inc. has 28 pending office actions as of November 2026, spread across 12 art units and 24 examiners.

Which USPTO examiner handles the most Novo Nordisk Inc. applications?

Gyan Chandra has the most, with 2 of Novo Nordisk Inc.'s pending office actions.

What technology area are Novo Nordisk Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month